Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05734066 · ClinicalTrials.gov registry record · Phase 1
Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma
A Phase 1 study of Ewing Sarcoma and Refractory Ewing Sarcoma, sponsored by Jazz Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 15
- Study locations
NCT05734066: Recruiting Phase 1 study of Ewing Sarcoma and Refractory Ewing Sarcoma, sponsored by Jazz Pharmaceuticals.
NCT05734066 is a Phase 1 study of Ewing Sarcoma and Refractory Ewing Sarcoma that is actively recruiting participants, run by Jazz Pharmaceuticals. The registered enrollment target is 60 participants, below the 107-participant average among 26 other Ewing Sarcoma trials with a reported enrollment target (44% lower). The trial reports 15 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05734066, a Phase 1 study of Ewing Sarcoma and Refractory Ewing Sarcoma, is actively recruiting participants, sponsored by Jazz Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 15
- Study locations
Study Summary
This study is conducted in two phases. The phase 1 portion of the study evaluates the safety, tolerability, pharmacokinetics (PK), recommended phase 2 dose (RP2D), and effectiveness of lurbinectedin monotherapy in pediatric participants with previously treated solid tumors. This is followed by the phase 2 portion, to further assess the effectiveness and safety in pediatric and young adult participants with recurrent/refractory Ewing sarcoma.
Conditions Studied
Interventions
- DRUG Lurbinectedin
Study Locations (15)
California
- Children's Hospital of Los Angeles - Los Angeles
- Lucile Packard Children's Hospital - Palo Alto
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
- Nationwide Children's Hospital - Columbus
Texas
- Children's Health Dallas - Dallas
- The University of Texas MD Anderson Cancer Center - Houston
District of Columbia
- Children's National Hospital - Washington D.C.
Florida
- Johns Hopkins All Children's Hospital - St. Petersburg
Georgia
- Children's Healthcare of Atlanta at Arthur M. Blank Hospital - Atlanta
Maryland
- Johns Hopkins University - Baltimore
Michigan
- Corewell Health - Grand Rapids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2023-05-23 |
| Est. Completion | 2028-04-20 |
| Phase | Phase 1 |
What NCT05734066 shows while recruiting
NCT05734066 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 107-participant average among 26 other Ewing Sarcoma trials with a reported enrollment target (44% lower).
The record links to 3 conditions, with Ewing Sarcoma appearing as the primary indexed condition, and to 1 intervention - of which Lurbinectedin is the first listed.
NCT05734066 lists 15 locations in 12 states (California, Ohio, Texas).
Frequently Asked Questions
What is clinical trial NCT05734066 about?
NCT05734066 is a clinical study titled "Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma". This study is conducted in two phases. The phase 1 portion of the study evaluates the safety, tolerability, pharmacokinetics (PK), recommended phase 2 dose (RP2D), and effectiveness of lurbinectedin monotherapy in pediatric participants with previously treated solid tumors. This is followed by the p...
What is the current status of trial NCT05734066?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2023-05-23. Estimated completion is 2028-04-20.
What conditions does trial NCT05734066 study?
This clinical trial studies the following conditions: Ewing Sarcoma, Refractory Ewing Sarcoma, Relapsed Ewing Sarcoma.
What interventions are being tested in trial NCT05734066?
The interventions under investigation include: Lurbinectedin (DRUG).
Who is sponsoring clinical trial NCT05734066?
This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05734066 being conducted?
This trial has 15 study locations across California, District of Columbia, Florida, Georgia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ewing Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05734066's enrollment target sits among peer trials
60 14th of 26 higher than 13 of 26 other Ewing Sarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ewing Sarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
RECRUITING · Phase 1
-
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
RECRUITING · Phase 1
-
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
RECRUITING · Phase 1
-
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
RECRUITING · Phase 1
-
Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
RECRUITING · Phase 1
-
Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI